AORT vs. FNA, ATRI, SILK, EMBC, TMCI, SIBN, KIDS, MDXG, IRMD, and SKIN
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Paragon 28 (FNA), Atrion (ATRI), Silk Road Medical (SILK), Embecta (EMBC), Treace Medical Concepts (TMCI), SI-BONE (SIBN), OrthoPediatrics (KIDS), MiMedx Group (MDXG), Iradimed (IRMD), and Beauty Health (SKIN). These companies are all part of the "surgical & medical instruments" industry.
Artivion (NYSE:AORT) and Paragon 28 (NYSE:FNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
In the previous week, Paragon 28 had 8 more articles in the media than Artivion. MarketBeat recorded 11 mentions for Paragon 28 and 3 mentions for Artivion. Artivion's average media sentiment score of 0.64 beat Paragon 28's score of 0.32 indicating that Artivion is being referred to more favorably in the media.
Paragon 28 received 13 more outperform votes than Artivion when rated by MarketBeat users. Likewise, 77.42% of users gave Paragon 28 an outperform vote while only 64.71% of users gave Artivion an outperform vote.
86.4% of Artivion shares are owned by institutional investors. Comparatively, 63.6% of Paragon 28 shares are owned by institutional investors. 6.6% of Artivion shares are owned by company insiders. Comparatively, 19.5% of Paragon 28 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Artivion has a net margin of -8.67% compared to Paragon 28's net margin of -22.11%. Artivion's return on equity of 3.02% beat Paragon 28's return on equity.
Artivion currently has a consensus target price of $23.50, suggesting a potential upside of 11.06%. Paragon 28 has a consensus target price of $19.33, suggesting a potential upside of 56.55%. Given Paragon 28's higher probable upside, analysts clearly believe Paragon 28 is more favorable than Artivion.
Artivion has higher revenue and earnings than Paragon 28. Artivion is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.
Artivion has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Summary
Paragon 28 beats Artivion on 9 of the 17 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Artivion Competitors List
Related Companies and Tools